Skip to main content
Erschienen in: BMC Cancer 1/2024

Open Access 01.12.2024 | Research

Analysis of related factors for pathological upgrading of cervical biopsy from CIN3 to cancer after conical resection

verfasst von: Zhifang Li, Guiju Zhou, Longfan Jiang, Mengjie Wang

Erschienen in: BMC Cancer | Ausgabe 1/2024

Abstract

Background

To investigate related factors for postoperative pathological upgrading of cervical biopsy to cervical cancer (CC) in patients with cervical intraepithelial neoplasia (CIN)3 after conical resection.

Methods

This retrospective study collected data from patients diagnosed with CIN3 by cervical biopsies at the author’s Hospital between January 2012 and December 2022. The primary outcome was the pathological results of patients after conical resection. The pathological findings were categorized into the pathological upgrading group if postoperative pathology indicated CC, while those with normal, inflammatory, or cervical precancerous lesions were classified into the pathological non-upgrading group. The factors associated with upgrading were identified using multivariable logistic regression analysis.

Results

Among 511 patients, there were 125 patients in the pathological upgrading group (24.46%). The patients in the upgrading group were younger (47.68 ± 9.46 vs. 52.11 ± 7.02, P < 0.001), showed a lower proportion of menopausal women (38.40% vs. 53.02%, P = 0.0111), a lower proportion of HSIL (40.00% vs. 57.77%, P = 0.001), a higher rate of HPV-16/18 positive (25.60% vs. 17.36%, P = 0.011), a higher rate of contact bleeding (54.40% vs. 21.50%, P < 0.001), lower HDL levels (1.31 ± 0.29 vs. 1.37 ± 0.34 mmol/L, P = 0.002), higher neutrophil counts (median, 3.50 vs. 3.10 × 109/L, P = 0.001), higher red blood cell counts (4.01 ± 0.43 vs. 3.97 ± 0.47 × 1012/L, P = 0.002), higher platelet counts (204.84 ± 61.24 vs. 187.06 ± 73.66 × 109/L, P = 0.012), and a smaller platelet volume (median, 11.50 vs. 11.90 fL, P = 0.002).The multivariable logistic regression analysis showed that age (OR = 0.90, 95% CI: 0.86–0.94, P < 0.001), menopausal (OR = 2.68, 95% CI: 1.38–5.22, P = 0.004), contact bleeding (OR = 4.80, 95% CI: 2.91–7.91, P < 0.001), and mean platelet volume (OR = 0.83, 95% CI: 0.69–0.99, P = 0.038) were independently associated with pathological upgrading from CIN3 to CC after conical resection.

Conclusion

Age, menopausal, contact bleeding, and mean platelet volume are risk factors of pathological upgrading from CIN3 to CC after conical resection, which could help identify high risk and susceptible patients of pathological upgrading to CC.
Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Background

Cervical cancer (CC) is a malignancy originating in the transformation zone of the cervix, most commonly in squamous cells [1]. It is the second most common cancer in women worldwide and the third most common cause of female cancer mortality [13]. The types of CC include squamous cell carcinoma, invasive adenocarcinoma, small cell neuroendocrine carcinoma, and other rare histologic types [2, 4]. There is a causal link between persistent infection and oncogenic types of human papillomavirus (HPV), most commonly HPV-16 and HPV-18, which are sexually transmissible pathogens [1, 2, 5]. squamous intraepithelial lesion (SIL) category which encompasses a spectrum of squamous cell lesions starting from the precancerous lesions of low-grade SIL (LSIL) to high-grade SIL (HSIL), and ultimately invasive squamous cell carcinoma [1, 2, 5].. Of note, the regression of CIN can occur, with higher rates of regression seen with lower grades of CIN [6]. Cervical cytology screening in the United States of America has been associated with a > 70% reduction in CC incidence and mortality since the mid-1970s [7]. Women with abnormal cytology are usually referred for a biopsy [8, 9].
The timely detection of CIN3 is the cornerstone of CC screening guidelines [9, 10]. Indeed, CIN3 carries a risk of developing into in situ and invasive CC, but a CIN3 lesion at biopsy can also “hide” a more advanced lesion. Indeed, a biopsy takes only a small part of a lesion, and it is possible to miss the foci of most advanced pathologies. Hence, guidelines advocate the surgical removal of CIN3 lesions [2, 4, 9]. Indeed, a pathological upgrade to CC can be observed after surgery in about 10-11% of the patients [11, 12].
Still, determining in advance the patients in whom there is a greater probability of finding CC after CIN3 removal would be more conducive to improving patient outcomes by identifying patients requiring more urgent treatments. Wang et al. [12] reported that image quality of colposcopy images, atypical blood vessels, biopsy sampling method, and visible lesion area of the cervix were independently associated with CC after surgery for CIN3. Some of these factors are subjective and based on the physician’s experience and judgment. On the other hand, Jia et al. [11] reported more objective factors independently associated with CC after CIN3 removal, i.e., postmenopausal period ≥ 5 years, endocervical glandular involvement, endocervical curettage, and HPV16/18 infection.
Therefore, this study aims to investigate risk factors for postoperative pathological upgrading of cervical biopsy from CIN3 to CC after conical resection. The results could help early identify high-risk and susceptible individuals with CC and facilitates precise interventions.

Methods

Data collection

This retrospective study collected data from patients diagnosed with CIN3 by cervical biopsies at the author’s Hospital between January 2012 and December 2022. Inclusion criteria: (1) age 30–75 years old; (2) available HPV and cervical liquid-based cytological examination results; (3) definitive diagnosis of CIN3 by colposcopy examination results and cervical multi-point biopsy pathology, (4) underwent loop electrosurgical excision procedure (LEEP); (5) underwent hysterectomy. Exclusion criteria: (1) incomplete clinical data, (2) cervical biopsy pathology suspicious for or not excluding invasive CC, or (3) concurrent other malignancies. This study was approved by the medical ethics committee of the author’s Hospital. The requirement for informed consent was waived due to the retrospective nature of the study.

Data collection and definitions

Clinical data were gathered through the electronic medical record system, including age, gravidity, parity, menopausal status, ThinPrep Cytology Test (TCT), high-risk HPV infection, involvement of glandular tissue, clinical symptoms, and preoperative laboratory test results. The TCT results were categorized into atypical squamous cells -cannot exclude high-grade squamous intraepithelial lesion (ASC-H), atypical glandular cells (AGC), high-grade squamous intraepithelial lesion (HSIL), negative for intraepithelial lesion or malignancy (NILM), atypical squamous cells (ASC), and low-grade squamous intraepithelial lesion (LSIL). ASC-H, AGC, and HSIL were grouped as the HSIL category, while NILM, ASC, and LSIL were grouped as the non-HSIL category. High-risk HPV infection was classified as HPV16/18 positive (considered positive if either HPV16 or HPV18 was detected, even in combination with other HPV types) or other high-risk types, excluding HPV16 and HPV18. The additional high-risk HPV types were 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. Cases with no relevant tests or HPV negativity were noted. Clinical symptoms encompassed contact bleeding (bleeding during sexual intercourse or vaginal bleeding), abnormal vaginal discharge (vaginal flow or abnormal discharge), or being asymptomatic with cervical lesions detected during routine physical examination. Laboratory indicators included high-density lipoprotein (HDL), albumin, lymphocyte count, monocyte count, neutrophil count, eosinophil count, red blood cell count, hemoglobin levels, hematocrit, red cell distribution width, platelet count, mean platelet volume, and fibrinogen.

Outcomes

The primary outcome was the pathological results of patients after conical resection. The pathological findings were categorized into the pathological upgrading group if postoperative pathology indicated CC, while those with normal, inflammatory, or cervical precancerous lesions were classified into the pathological non-upgrading group.

Statistical analysis

Statistical analysis was conducted using SPSS 22.0 (IBM Corp., Armonk, NY, USA). Missing values were handled through regression imputation. Continuous variables underwent normality testing; if they followed a normal distribution, an independent sample t-test was used for between-group comparisons. If the variables did not adhere to a normal distribution, the Wilcoxon-Mann-Whitney test was applied. Categorical variables were presented as n (%), and the chi-square test was used. Binary logistic regression analysis was used to explore independent factors associated with occult CC; variables with a P-value < 0.05 in the univariable analyses were included in the multivariable analysis. A two-sided P-value P < 0.05 was considered statistically significant.

Results

A total of 534 patients met the inclusion criteria, but 23 were excluded due to incomplete clinical data, leaving 511 patients included. Among them, there were 125 patients in the pathological upgrading group (upgrading rate of 24.46%), and the non-upgrading group comprised 386 patients.
The characteristics of the patients are presented in Table 1. Compared with the non-upgrading group, the patients in the upgrading group were younger (47.68 ± 9.46 vs. 52.11 ± 7.02, P < 0.001), showed a lower proportion of menopausal women (38.40% vs. 53.02%, P = 0.0111), a lower proportion of HSIL (40.00% vs. 57.77%, P = 0.001), a higher rate of HPV-16/18 positive (25.60% vs. 17.36%, P = 0.011), a higher rate of contact bleeding (54.40% vs. 21.50%, P < 0.001), lower HDL levels (1.31 ± 0.29 vs. 1.37 ± 0.34 mmol/L, P = 0.002), higher neutrophil counts (median, 3.50 vs. 3.10 × 109/L, P = 0.001), higher red blood cell counts (4.01 ± 0.43 vs. 3.97 ± 0.47 × 1012/L, P = 0.002), higher platelet counts (204.84 ± 61.24 vs. 187.06 ± 73.66 × 109/L, P = 0.012), and a smaller platelet volume (median, 11.50 vs. 11.90 fL, P = 0.002).
Table 1
Characteristics of the patients
Clinical Information
Pathological upgrading group (n = 125)
Pathological non-upgrading group (n = 386)
P
Age (years), Mean ± SD
47.68 ± 9.46
52.11 ± 7.02
< 0.001
Gravidity, Median (IQR)
3.00 (2.00 4.00)
3.00 (2.00 4.00)
0.302
Parity, Median (IQR)
2.00 (1.00 2.00)
2.00 (1.00 2.00)
0.252
Menopausal status, n (%)
  
0.011
Yes
48 (38.40)
202 (53.02)
 
No
73 (58.40)
179 (46.98)
 
TCT, n (%)
  
0.001
HSIL
50 (40.00)
223 (57.77)
 
Non-HSIL
33 (26.40)
83 (21.50)
 
Unknown
42 (33.60)
80 (20.73)
 
High-risk HPV infection, n (%)
  
0.011
HPV16/18 positive
32 (25.60)
67 (17.36)
 
Other high-risk types
16 (12.80)
74 (19.17)
 
Not checked
77 (61.60)
235 (60.88)
 
HPV negative, n (%)
0
10 (2.59)
 
Involvement of glandular tissue, n (%)
  
0.083
Yes
82 (69.81)
300 (77.92)
 
No
43 (30.19)
85 (22.08)
 
Clinical symptoms, n (%)
  
< 0.001
Contact bleeding
68 (54.40)
83 (21.50)
 
Abnormal vaginal discharge
12 (9.60)
39 (10.10)
 
Asymptomatic, detected during routine examination
45 (36.00)
264 (68.39)
 
High-density lipoprotein (mmol/L)
1.31 ± 0.29
1.37 ± 0.34
0.002
Albumin (g/L), Median (IQR)
41.10 (39.60 44.30)
41.90 (39.41 44.40)
0.560
Lymphocyte count (109/L), Median (IQR)
1.70 (1.35 2.20)
1.70 (1.40 2.00)
0.183
Monocyte count (109/L), Median (IQR)
0.39 (0.30 0.51)
0.37 (0.30 0.47)
0.305
Neutrophil count (109/L), Median (IQR)
3.50 (2.90 4.50)
3.10 (2.40 4.00)
0.001
Eosinophil count (109/L), Median (IQR)
0.10 (0.06 0.17)
0.09 (0.06 0.15)
0.254
Red blood cell count (1012/L)
4.01 ± 0.43
3.97 ± 0.47
0.002
Hemoglobin (g/L), Median (IQR)
121.00 (109.00 127.00)
118.50 (112.00 126.00)
0.881
Hematocrit (%), Median (IQR)
36.10 (32.95 38.20)
36.00 (34.10 38.10)
0.567
Red cell distribution width, Median (IQR)
42.90 (40.70 46.55)
43.70 (41.58 46.23)
0.089
Platelet count (109/L), Mean ± SD
204.84 ± 61.24
187.06 ± 73.66
0.012
Mean platelet volume (fl.), Median (IQR)
11.50 (10.60 12.30)
11.90 (11.00 12.90)
0.002
Fibrinogen (g/L), Median (IQR)
2.73 (2.32 3.11)
2.73 (2.39 3.06)
0.842
TCT: ThinPrep Cytology Test; HSIL: high-grade squamous intraepithelial lesion; HPV: human papillomavirus
The multivariable analysis of the factors associated with postoperative pathological upgrading to cervical cancer is shown in Table 2. Age (OR = 0.90, 95%CI: 0.86–0.94, P < 0.001), menopausal (OR = 2.68, 95%CI: 1.38–5.22, P = 0.004), contact bleeding (OR = 4.80, 95%CI: 2.91–7.91, P < 0.001), and mean platelet volume (OR = 0.83, 95%CI: 0.69–0.99, P = 0.038) were independently associated with a pathological upgrade to CC after surgery for CIN3 lesions.
Table 2
Multivariable logistic regression analysis for pathological upgrading of cervical biopsy from CIN3 to cancer after conical resection
Variables
Univariable model
Multivariable model
OR (95% CI)
P
OR (95% CI)
P
Age (years)
0.92 (0.90, 0.95)
< 0.001
0.90 (0.86, 0.94)
< 0.001
Gravidity
0.95 (0.84, 1.07)
0.400
  
Parity
0.86 (0.68, 1.08)
0.201
  
Menopausal Status
    
Yes
0.58 (0.38, 0.88)
0.011
2.68 (1.38, 5.22)
0.004
No
ref
 
ref
 
TCT
    
HSIL
ref
 
ref
 
Non-HSIL
1.77 (1.07, 2.94)
0.027
1.80 (0.99, 3.29)
0.055
Unknown
2.34 (1.44, 3.80)
0.001
1.61 (0.91, 2.89)
0.098
High-risk HPV infection
    
HPV16/18 positive
ref
 
ref
 
Other high-risk types
0.45 (0.23, 0.90)
0.023
0.54 (0.25, 1.15)
0.111
Not checked
0.69 (0.42, 1.12)
0.135
0.80 (0.44, 1.43)
0.443
HPV negative
-
-
-
-
Involvement of glandular tissue
    
Yes
0.66 (0.41, 1.06)
0.084
  
No
ref
   
Clinical symptoms
    
Contact bleeding
4.81 (3.06, 7.54)
< 0.001
4.80 (2.91, 7.91)
< 0.001
Abnormal vaginal discharge
1.81 (0.88, 3.71)
0.108
1.41 (0.63, 3.15)
0.406
Asymptomatic, detected during routine examination
ref
 
ref
 
High-density lipoprotein
0.71 (0.37, 1.35)
0.298
  
Albumin
0.98 (0.94, 1.03)
0.464
  
Lymphocyte count
1.12 (0.87, 1.44)
0.389
  
Monocyte count
1.19 (0.52, 2.74)
0.680
  
Neutrophil count
1.16 (1.04, 1.29)
0.008
1.09 (0.96, 1.23)
0.189
Eosinophil count
1.77 (0.35, 8.90)
0.487
  
Red blood cell count
1.26 (0.79, 2.02)
0.332
  
Hemoglobin
1.00 (0.98, 1.01)
0.562
  
Hematocrit
0.96 (0.91, 1.02)
0.210
  
Red cell distribution width
1.02 (0.98, 1.05)
0.370
  
Platelet count
1.00 (1.00, 1.01)
0.030
1.00 (1.00, 1.00)
0.714
Mean platelet volume
0.83 (0.71, 0.96)
0.014
0.83 (0.69, 0.99)
0.038
Fibrinogen
1.01 (0.83, 1.22)
0.928
  
TCT: thinprep cytology test; HSIL: high-grade squamous intraepithelial lesion; HPV: human papillomavirus

Discussion

This retrospective study investigated the factors associated with postoperative pathological upgrading to CC in patients with CIN3 following cervical biopsy. The results indicated that the pathological postoperative upgrading rate after CIN3 diagnosis at biopsy was high, at about 24.46%. Age, menopausal, contact bleeding, and mean platelet volume were independently associated with a higher probability of pathological upgrading to CC.
In the present study, the upgrading rate was 24.46%, higher than the 11% reported by Jia et al. [11] and the 6% reported by Fan et al. [13]. The discrepancy among studies cannot be explained by the data collected in the present study. Patient selection could play a role, as well as the criteria applied to select the patients for surgery (the present study did not include the patients who did not undergo surgery). It should be examined in future studies.
A study reported that image quality of colposcopy images, atypical blood vessels, biopsy sampling method, and visible lesion area of the cervix were independently associated with CC after surgery for CIN3 [12]. These factors above can be subjective and dependent upon the physician’s experience. Another study reported that a postmenopausal period ≥ 5 years, endocervical glandular involvement, endocervical curettage, and HPV16/18 infection were associated with upgrading to CC, which are more objective factors [14]. In the present study, age (OR = 0.90), menopausal (OR = 2.68), contact bleeding (OR = 4.80), and mean platelet volume (OR = 0.83) were independently associated with a pathological upgrade to CC after surgery for CIN3 lesions. The discrepancies among factors can be due to the available data in the retrospective studies.
Age is associated with the development of CC, and the peak age of incidence is 40–49 years, and most women develop CC before the age of 50 [5]. Accordingly, in the present study, the patients in the upgrading group were younger than those in the no-upgrading group. Still, such result must be considered with caution since cervical screening tend to decrease with age, which could affect the apparent incidence of CC [15]. A bimodal incidence of CC has been reported, with peaks at 30–39 and 60–69 years [16]. In the present study, very few women fell in the 60–69 age range. Additional studies are necessary to confirm the association of age with the upgrade of CIN3 at biopsy to CC at surgery.
Nevertheless, age and menopause are covariates. The decline in estrogen levels at menopause induces reductions in squamous epithelial cells, stromal blood vessels, and glycogen cell content. Hence, the sensitivity of acetic acid and iodine staining decreases [13, 1719]. Suspicious lesions become difficult to evaluate and can be missed [20]. Indeed, Costa et al. [20] showed that after 50 years, the risk of missing a CC by colposcopy increases by 11 folds compared with patients < 30 years. Considering that menopause occurs in most Chinese women around 49–50 years of age [2123] (80% are menopausal by 54 years [24]), menopause could be considered a risk factor for upgrading to CC after surgery for CIN3 lesions, as observed in the present study.
Vaginal bleeding or blood-stained vaginal discharge can be a sign of CC [2528], but the risk of CC in women with postcoital bleeding is less clear [29]. In the present study, all women were diagnosed with CIN3 lesions. Vaginal bleeding is a sign that should prompt a medical consultation in the general population [27, 28]. In patients with a proven cervical lesion, additional signs such as vaginal bleeding could hint toward more severe lesions, as suggested by the present study.
The present study identified a decreased mean platelet volume as being associated with the pathological postoperative upgrading to CC in patients with CIN3 lesions at biopsy. Shen et al. [30] and Qin et al. [31] reported that a decreased mean platelet volume was associated with CC development and could even be used as a screening tool. In patients with CC, a decreased mean platelet volume is also associated with a poorer prognosis, indicating more aggressive or advanced disease [32, 33]. Platelets have complex relationships with cancer cells and contribute to tumor growth, angiogenesis, invasion, and dissemination [34, 35]. The mean platelet volume is associated with inflammatory conditions, including cancer [36, 37].It is suggested that the influence of HPV virus on blood cells is mainly reflected in the volume of platelets.
However, there were several limitations in this study. Firstly, this was a single-center study and with limited samples, which might have introduced selection bias. Secondly, this is a retrospective study, which is susceptible to investigator bias and recall bias. Thirdly, as an observational study, the available evidence was insufficient to definitively establish a causal relationship. Further studies were needed to investigate the potential risk factors of CIN3 upgrading to CC.
In conclusion, the pathological postoperative upgrading rate after CIN3 diagnosis at biopsy was high, at about 24.46%. Age, menopausal, contact bleeding, and mean platelet volume are objective parameters that could be used to identify patients with a higher probability of pathological upgrading to CC. Future studies should validate those factors to develop a nomogram that could be used to stratify the patients.

Declarations

All procedures were performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. This study was approved by the medical Ethics Committee of Anqing Municipal Hospital. The requirement for individual Informed consent was waived by the medical Ethics Committee of Anqing Municipal Hospital because of the retrospective nature of the study. All methods were carried out in accordance with relevant guidelines and regulations.
Not Applicable.

Competing interests

The authors declare no competing interests.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Berman TA, Schiller JT. Human papillomavirus in cervical cancer and oropharyngeal cancer: one cause, two diseases. Cancer. 2017;123:2219–29.CrossRefPubMed Berman TA, Schiller JT. Human papillomavirus in cervical cancer and oropharyngeal cancer: one cause, two diseases. Cancer. 2017;123:2219–29.CrossRefPubMed
2.
Zurück zum Zitat Marth C, Landoni F, Mahner S, et al. Cervical cancer: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv72–83.CrossRefPubMed Marth C, Landoni F, Mahner S, et al. Cervical cancer: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv72–83.CrossRefPubMed
3.
Zurück zum Zitat Sung H, Ferlay J, Siegel RL, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.CrossRefPubMed Sung H, Ferlay J, Siegel RL, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.CrossRefPubMed
4.
Zurück zum Zitat NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Cervical Cancer. Version 1.2024. Fort Washington: National Comprehensive Cancer Network; 2023. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Cervical Cancer. Version 1.2024. Fort Washington: National Comprehensive Cancer Network; 2023.
5.
Zurück zum Zitat Ahmed Alrajjal,Vaishali Pansare,Moumita Saha Roy Choudhury. Squamous intraepithelial lesions (SIL: LSIL, HSIL, ASCUS, ASC-H, LSIL-H) of Uterine Cervix and Bethesda System. CytoJournal 2021;18(16). Ahmed Alrajjal,Vaishali Pansare,Moumita Saha Roy Choudhury. Squamous intraepithelial lesions (SIL: LSIL, HSIL, ASCUS, ASC-H, LSIL-H) of Uterine Cervix and Bethesda System. CytoJournal 2021;18(16).
7.
Zurück zum Zitat Gibb RK, Martens MG. The impact of liquid-based cytology in decreasing the incidence of cervical cancer. Rev Obstet Gynecol. 2011;4:S2–11.PubMedPubMedCentral Gibb RK, Martens MG. The impact of liquid-based cytology in decreasing the incidence of cervical cancer. Rev Obstet Gynecol. 2011;4:S2–11.PubMedPubMedCentral
8.
Zurück zum Zitat Wentzensen N, Walker JL, Gold MA, et al. Multiple biopsies and detection of cervical cancer precursors at colposcopy. J Clin Oncol. 2015;33:83–9.CrossRefPubMed Wentzensen N, Walker JL, Gold MA, et al. Multiple biopsies and detection of cervical cancer precursors at colposcopy. J Clin Oncol. 2015;33:83–9.CrossRefPubMed
9.
Zurück zum Zitat Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP Risk-Based Management Consensus guidelines for abnormal cervical Cancer screening tests and Cancer precursors. J Low Genit Tract Dis. 2020;24:102–31.CrossRefPubMedPubMedCentral Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP Risk-Based Management Consensus guidelines for abnormal cervical Cancer screening tests and Cancer precursors. J Low Genit Tract Dis. 2020;24:102–31.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Massad LS, Einstein MH, Huh WK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol. 2013;121:829–46.CrossRefPubMed Massad LS, Einstein MH, Huh WK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol. 2013;121:829–46.CrossRefPubMed
11.
Zurück zum Zitat Jia M, Lan C, Niu J, Liang Y. Risk factors for pathological upgrading in perimenopausal women with cervical intraepithelial neoplasia grade 2/3 following conization. Med (Baltim). 2022;101:e31368.CrossRef Jia M, Lan C, Niu J, Liang Y. Risk factors for pathological upgrading in perimenopausal women with cervical intraepithelial neoplasia grade 2/3 following conization. Med (Baltim). 2022;101:e31368.CrossRef
12.
Zurück zum Zitat Wang Y, Wang J, Mei H. Diagnosis of cervical intraepithelial neoplasia and invasive cervical carcinoma by cervical biopsy under Colposcopy and analysis of factors influencing. Emerg Med Int. 2022;2022:9621893.CrossRefPubMedPubMedCentral Wang Y, Wang J, Mei H. Diagnosis of cervical intraepithelial neoplasia and invasive cervical carcinoma by cervical biopsy under Colposcopy and analysis of factors influencing. Emerg Med Int. 2022;2022:9621893.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Fan A, Zhang L, Wang C, Wang Y, Han C, Xue F. Analysis of clinical factors correlated with the accuracy of colposcopically directed biopsy. Arch Gynecol Obstet. 2017;296:965–72.CrossRefPubMed Fan A, Zhang L, Wang C, Wang Y, Han C, Xue F. Analysis of clinical factors correlated with the accuracy of colposcopically directed biopsy. Arch Gynecol Obstet. 2017;296:965–72.CrossRefPubMed
14.
Zurück zum Zitat Fang Y, Gong AY, Haller ST, Dworkin LD, Liu Z, Gong R. The ageing kidney: molecular mechanisms and clinical implications. Ageing Res Rev. 2020;63:101151.CrossRefPubMedPubMedCentral Fang Y, Gong AY, Haller ST, Dworkin LD, Liu Z, Gong R. The ageing kidney: molecular mechanisms and clinical implications. Ageing Res Rev. 2020;63:101151.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Castanon A, Landy R, Cuzick J, Sasieni P. Cervical screening at age 50–64 years and the risk of cervical cancer at age 65 years and older: population-based case control study. PLoS Med. 2014;11:e1001585.CrossRefPubMedPubMedCentral Castanon A, Landy R, Cuzick J, Sasieni P. Cervical screening at age 50–64 years and the risk of cervical cancer at age 65 years and older: population-based case control study. PLoS Med. 2014;11:e1001585.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Giannella L, Fodero C, Boselli F, Mfuta K, Rubino T, Prandi S. Age-related changes in the diagnostic assessment of women with severe cervical lesions. Climacteric. 2015;18:617–23.CrossRefPubMed Giannella L, Fodero C, Boselli F, Mfuta K, Rubino T, Prandi S. Age-related changes in the diagnostic assessment of women with severe cervical lesions. Climacteric. 2015;18:617–23.CrossRefPubMed
18.
Zurück zum Zitat Giannella L, Giorgi Rossi P, Delli Carpini G, et al. Age-related distribution of uncommon HPV genotypes in cervical intraepithelial neoplasia grade 3. Gynecol Oncol. 2021;161:741–7.CrossRefPubMed Giannella L, Giorgi Rossi P, Delli Carpini G, et al. Age-related distribution of uncommon HPV genotypes in cervical intraepithelial neoplasia grade 3. Gynecol Oncol. 2021;161:741–7.CrossRefPubMed
19.
Zurück zum Zitat Giannella L, Mfuta K, Gardini G, Rubino T, Fodero C, Prandi S. High-grade CIN on cervical biopsy and predictors of the subsequent cone histology results in women undergoing immediate conization. Eur J Obstet Gynecol Reprod Biol. 2015;186:68–74.CrossRefPubMed Giannella L, Mfuta K, Gardini G, Rubino T, Fodero C, Prandi S. High-grade CIN on cervical biopsy and predictors of the subsequent cone histology results in women undergoing immediate conization. Eur J Obstet Gynecol Reprod Biol. 2015;186:68–74.CrossRefPubMed
20.
Zurück zum Zitat Costa S, Nuzzo MD, Rubino A, et al. Independent determinants of inaccuracy of colposcopically directed punch biopsy of the cervix. Gynecol Oncol. 2003;90:57–63.CrossRefPubMed Costa S, Nuzzo MD, Rubino A, et al. Independent determinants of inaccuracy of colposcopically directed punch biopsy of the cervix. Gynecol Oncol. 2003;90:57–63.CrossRefPubMed
21.
Zurück zum Zitat Li L, Wu J, Pu D, et al. Factors associated with the age of natural menopause and menopausal symptoms in Chinese women. Maturitas. 2012;73:354–60.CrossRefPubMed Li L, Wu J, Pu D, et al. Factors associated with the age of natural menopause and menopausal symptoms in Chinese women. Maturitas. 2012;73:354–60.CrossRefPubMed
22.
Zurück zum Zitat Yang D, Haines CJ, Pan P, et al. Menopausal symptoms in mid-life women in southern China. Climacteric. 2008;11:329–36.CrossRefPubMed Yang D, Haines CJ, Pan P, et al. Menopausal symptoms in mid-life women in southern China. Climacteric. 2008;11:329–36.CrossRefPubMed
23.
Zurück zum Zitat Lan Y, Huang Y, Song Y, et al. Prevalence, severity, and associated factors of menopausal symptoms in middle-aged Chinese women: a community-based cross-sectional study in southeast China. Menopause. 2017;24:1200–7.CrossRefPubMed Lan Y, Huang Y, Song Y, et al. Prevalence, severity, and associated factors of menopausal symptoms in middle-aged Chinese women: a community-based cross-sectional study in southeast China. Menopause. 2017;24:1200–7.CrossRefPubMed
24.
Zurück zum Zitat Du L, Xu B, Huang C, Zhu L, He N. Menopausal symptoms and Perimenopausal Healthcare-seeking behavior in women aged 40–60 years: A Community-based cross-sectional survey in Shanghai, China. Int J Environ Res Public Health. 2020;17. Du L, Xu B, Huang C, Zhu L, He N. Menopausal symptoms and Perimenopausal Healthcare-seeking behavior in women aged 40–60 years: A Community-based cross-sectional survey in Shanghai, China. Int J Environ Res Public Health. 2020;17.
26.
Zurück zum Zitat Patibandla JR, Fehniger JE, Levine DA, Jelinic P. Small cell cancers of the female genital tract: Molecular and clinical aspects. Gynecol Oncol. 2018;149:420–7.CrossRefPubMed Patibandla JR, Fehniger JE, Levine DA, Jelinic P. Small cell cancers of the female genital tract: Molecular and clinical aspects. Gynecol Oncol. 2018;149:420–7.CrossRefPubMed
27.
Zurück zum Zitat Hutchcraft ML, Miller RW. Bleeding from gynecologic malignancies. Obstet Gynecol Clin North Am. 2022;49:607–22.CrossRefPubMed Hutchcraft ML, Miller RW. Bleeding from gynecologic malignancies. Obstet Gynecol Clin North Am. 2022;49:607–22.CrossRefPubMed
28.
Zurück zum Zitat Adams T, Denny L. Abnormal vaginal bleeding in women with gynaecological malignancies. Best Pract Res Clin Obstet Gynaecol. 2017;40:134–47.CrossRefPubMed Adams T, Denny L. Abnormal vaginal bleeding in women with gynaecological malignancies. Best Pract Res Clin Obstet Gynaecol. 2017;40:134–47.CrossRefPubMed
29.
Zurück zum Zitat Shapley M, Jordan J, Croft PR. A systematic review of postcoital bleeding and risk of cervical cancer. Br J Gen Pract. 2006;56:453–60.PubMedPubMedCentral Shapley M, Jordan J, Croft PR. A systematic review of postcoital bleeding and risk of cervical cancer. Br J Gen Pract. 2006;56:453–60.PubMedPubMedCentral
30.
Zurück zum Zitat Shen WJ, Fu S, Li N, et al. Decreased Mean platelet volume is Associated with Cervical Cancer Development. Asian Pac J Cancer Prev. 2017;18:1769–72.PubMedPubMedCentral Shen WJ, Fu S, Li N, et al. Decreased Mean platelet volume is Associated with Cervical Cancer Development. Asian Pac J Cancer Prev. 2017;18:1769–72.PubMedPubMedCentral
31.
Zurück zum Zitat Qin S, Chen S, Qin S, Chen H, Hu Z, Li S. Correlation between pretreatment hematologic parameters and cervical Cancer patients undergoing hysterectomy: a retrospective study. Clin Lab. 2020;66. Qin S, Chen S, Qin S, Chen H, Hu Z, Li S. Correlation between pretreatment hematologic parameters and cervical Cancer patients undergoing hysterectomy: a retrospective study. Clin Lab. 2020;66.
32.
Zurück zum Zitat Deng Q, Long Q, Liu Y, Yang Z, Du Y, Chen X. Prognostic value of preoperative peripheral blood mean platelet volume/platelet count ratio (MPV/PC) in patients with resectable cervical cancer. BMC Cancer. 2021;21:1282.CrossRefPubMedPubMedCentral Deng Q, Long Q, Liu Y, Yang Z, Du Y, Chen X. Prognostic value of preoperative peripheral blood mean platelet volume/platelet count ratio (MPV/PC) in patients with resectable cervical cancer. BMC Cancer. 2021;21:1282.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Wang JM, Wang Y, Huang YQ, et al. Prognostic values of platelet-Associated indicators in Resectable Cervical Cancer. Dose Response. 2019;17:1559325819874199.PubMedPubMedCentral Wang JM, Wang Y, Huang YQ, et al. Prognostic values of platelet-Associated indicators in Resectable Cervical Cancer. Dose Response. 2019;17:1559325819874199.PubMedPubMedCentral
34.
Zurück zum Zitat Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost. 2011;9:237–49.CrossRefPubMed Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost. 2011;9:237–49.CrossRefPubMed
35.
Zurück zum Zitat Goubran HA, Stakiw J, Radosevic M, Burnouf T. Platelet-cancer interactions. Semin Thromb Hemost. 2014;40:296–305.CrossRefPubMed Goubran HA, Stakiw J, Radosevic M, Burnouf T. Platelet-cancer interactions. Semin Thromb Hemost. 2014;40:296–305.CrossRefPubMed
36.
Zurück zum Zitat Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des. 2011;17:47–58.CrossRefPubMed Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des. 2011;17:47–58.CrossRefPubMed
37.
Zurück zum Zitat Gu M, Zhai Z, Huang L, et al. Pre-treatment mean platelet volume associates with worse clinicopathologic features and prognosis of patients with invasive breast cancer. Breast Cancer. 2016;23:752–60.CrossRefPubMed Gu M, Zhai Z, Huang L, et al. Pre-treatment mean platelet volume associates with worse clinicopathologic features and prognosis of patients with invasive breast cancer. Breast Cancer. 2016;23:752–60.CrossRefPubMed
Metadaten
Titel
Analysis of related factors for pathological upgrading of cervical biopsy from CIN3 to cancer after conical resection
verfasst von
Zhifang Li
Guiju Zhou
Longfan Jiang
Mengjie Wang
Publikationsdatum
01.12.2024
Verlag
BioMed Central
Erschienen in
BMC Cancer / Ausgabe 1/2024
Elektronische ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12186-w

Weitere Artikel der Ausgabe 1/2024

BMC Cancer 1/2024 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.